TYRP1 and neoplasm: For this purpose IL-2/mAb, IL-2WTFc or IL-23XFc treatment was administered in combination with a monoclonal antibody targeting the B16F10 tumour antigen tyrosinase-related protein 1 (TRP-1) (Fig. 6a).